Details of the Drug

General Information of Drug (ID: DM4O17U)

Drug Name
VLTS-589
Synonyms Deltavasc; Del-1 gene therapy, Valentis; Gene therapy (Del-1, PINC), Valentis
Indication
Disease Entry ICD 11 Status REF
Peripheral vascular disease BD4Z Phase 2 [1]
Cross-matching ID
DrugBank ID
DB05430
TTD ID
D0D7DU

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-V/beta-3 (ITGAV/B3) TT69TQN ITAV_HUMAN-ITB3_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Peripheral vascular disease
ICD Disease Classification BD4Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Integrin alpha-V/beta-3 (ITGAV/B3) DTT ITGAV-ITGB3 8.19E-02 -0.16 -0.46
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00068133) Trial of VLTS-589 in Subjects With Intermittent Claudication. U.S. National Institutes of Health.
2 AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.